医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

バイオテクノロジー

Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration

Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration

その他ヘルスバイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: BML Collaboration Labcorp Plans Laboratory Expansion in Japan Through

2022年06月29日

CORRECTING and REPLACING Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

CORRECTING and REPLACING Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: CORRECTING and REPLACING Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

2022年06月28日

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator

バイオテクノロジーヘルスケアヘルス一般眼科医療製薬　 TimeLine: 116 A Novel Nrf2 Activator Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO

2022年06月27日

Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

2022年06月27日

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

バイオテクノロジーヘルスケアヘルス一般臨床試験製薬　 TimeLine: Results from Phase Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

2022年06月27日

US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510

US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: 2a Trial of First-in-Class Pancreatic Cancer Treatment PBP1510 US FDA Approves Prestige Biopharma’s IND for Phase

2022年06月27日

Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen Trastuzumab Deruxtecan Recommended for Approval in the

2022年06月27日

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

SINOVAC COVID-19 Vaccine Is Conditionally Registered In South Africa

バイオテクノロジーヘルスケア製薬　 TimeLine: Sinovac COVID Vaccine Is Conditionally Registered In South Africa

2022年06月25日

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

バイオテクノロジーヘルスケア医療機器腫瘍学臨床試験製薬　 TimeLine: burosumab TIO

2022年06月24日

Pictor Receives CE Mark for its PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster

Pictor Receives CE Mark for its PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Booster

その他ヘルスバイオテクノロジーヘルスケア医療用品感染症製薬　 TimeLine: COVID-19 Booster Indicating Whether Patients Require its PictArray Pictor Receives CE Mark for SARS-CoV-2 Antibody Test

2022年06月22日